Read More

Forma Therapeutics’ FT-7051 Is Well-tolerated And Demonstrates Evidence If Activity In Initial Results From Ongoing Phase 1 Courage Study In Men With Metastatic Castration-resistant Prostate Cancer

Forma Therapeutics Holdings, Inc. (NASDAQ:FMTX), a clinical-stage biopharmaceutical company focused on sickle cell disease, prostate cancer and other rare hematologic diseases and cancers, today announced positive

FMTX